Drugs / MYMD-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05077865 | Apr → Aug 2021 | Hashimoto thyroiditis | TNF Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05283486 | Feb 2022 → Jun 2023 | muscular atrophy | TNF Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MYMD-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05283486 ↗ |
| Route | Oral | “single oral dose of MYMD1 capsule” NCT05077865 ↗ |